Precision BioSciences (NASDAQ:DTIL – Get Rating) announced its quarterly earnings results on Monday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.08, MarketWatch Earnings reports. Precision BioSciences had a negative return on equity of 34.78% and a negative net margin of 26.49%. During the same period last year, the firm posted ($0.33) earnings per share.
DTIL traded up $0.13 during trading on Tuesday, hitting $1.88. The company’s stock had a trading volume of 56,832 shares, compared to its average volume of 656,905. The firm’s 50 day moving average price is $2.95 and its 200-day moving average price is $5.71. Precision BioSciences has a twelve month low of $1.73 and a twelve month high of $14.38. The stock has a market cap of $114.45 million, a PE ratio of -3.44 and a beta of 1.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.50 and a quick ratio of 4.50.
DTIL has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Precision BioSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 19th. The Goldman Sachs Group decreased their target price on shares of Precision BioSciences from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 16th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.60.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ensign Peak Advisors Inc acquired a new stake in shares of Precision BioSciences in the 4th quarter worth about $73,000. MetLife Investment Management LLC grew its stake in shares of Precision BioSciences by 56.6% in the 4th quarter. MetLife Investment Management LLC now owns 19,040 shares of the company’s stock worth $141,000 after purchasing an additional 6,885 shares during the last quarter. Invesco Ltd. grew its position in Precision BioSciences by 73.4% in the second quarter. Invesco Ltd. now owns 20,235 shares of the company’s stock worth $254,000 after buying an additional 8,566 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Precision BioSciences during the fourth quarter worth $151,000. Finally, Vident Investment Advisory LLC acquired a new stake in Precision BioSciences during the 4th quarter worth about $161,000. 51.65% of the stock is currently owned by institutional investors.
Precision BioSciences Company Profile (Get Rating)
Precision BioSciences, Inc, a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
- Get a free copy of the StockNews.com research report on Precision BioSciences (DTIL)
- If PetMeds Is A Good Buy There Will Be A Better Signal
- Insiders Buy Occidental Petroleum Ahead Of Q1 Earnings
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Follow The Money To Cigna
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.